Publication
Tert expression in meningiomas predicts progression-free survival independent of tert promoter mutation
| dc.contributor.author | Gui, Chloe | |
| dc.contributor.author | Wang, Justin | |
| dc.contributor.author | Patil, Vikas | |
| dc.contributor.author | Landry, Alexander | |
| dc.contributor.author | Castelo-Branco, Pedro | |
| dc.contributor.author | Singh, Olivia | |
| dc.contributor.author | Tabori, Uri | |
| dc.contributor.author | Aldape, Kenneth | |
| dc.contributor.author | Behling, Felix | |
| dc.contributor.author | Barnholtz-Sloan, Jill | |
| dc.contributor.author | Horbinski, Craig | |
| dc.contributor.author | Tabatabai, Ghazaleh | |
| dc.contributor.author | Ajisebutu, Andrew | |
| dc.contributor.author | Liu, Jeff | |
| dc.contributor.author | Patel, Zeel | |
| dc.contributor.author | Yakubov, Rebeca | |
| dc.contributor.author | Kaloti, Ramneet | |
| dc.contributor.author | Ellenbogen, Yosef | |
| dc.contributor.author | Wilson, Christopher | |
| dc.contributor.author | Cohen-Gadol, Aaron | |
| dc.contributor.author | Tatagiba, Marcos | |
| dc.contributor.author | Sloan, Andrew | |
| dc.contributor.author | Holland, Eric | |
| dc.contributor.author | Chambless, Lola | |
| dc.contributor.author | Gao, Andrew | |
| dc.contributor.author | Chotai, Silky | |
| dc.contributor.author | Makarenko, Serge | |
| dc.contributor.author | Yip, Stephen | |
| dc.contributor.author | Nassiri, Farshad | |
| dc.contributor.author | Zadeh, Gelareh | |
| dc.date.accessioned | 2025-12-18T12:02:31Z | |
| dc.date.available | 2025-12-18T12:02:31Z | |
| dc.date.issued | 2025-11-01 | |
| dc.description.abstract | While TERT promoter mutation (TPM) has been es¬tablished as a marker of clinically aggressive meningiomas, this alteration is rare and found in less than 5% of all cases. However, a larger subset of meningiomas may exhibit aberrant TERT expression in the absence of TPMs. This study investigated the effect of TERT gene expression on clinical outcome in meningioma patients. METHODS: Clinical and mo¬lecular data were retrospectively collected on 1241 meningiomas, split into a Toronto discovery cohort and a multi-institutional validation co¬hort. Sanger sequencing and bulk RNA sequencing were used to determine TPM status and TERT gene expression. The effect of TERT expression on progression-free survival (PFS) was assessed using Kaplan-Meier and Cox regression analysis. RESULTS: While meningiomas with TPM showed expectedly higher TERT gene expression compared to wildtype (TP-WT) cases (p<0.0001), TERT expression was still detected in 28.7% (157/547) of TP-WT meningiomas. Meningiomas with TERT expression showed sig¬nificantly worse PFS compared to meningiomas without any TERT expres¬sion. In fact, WHO grade 1 meningiomas with TERT expression had PFS outcomes resembling WHO grade 2 meningiomas lacking TERT expression (p=0.59). In turn, WHO grade 2 meningiomas with TERT expression had clinical outcomes similar to WHO grade 3 meningiomas without TERT ex¬pression (p=0.42). Furthermore, the proportion of meningiomas expressing TERT as well as overall TERT expression levels increased with increasing WHO grade. Multivariable analysis showed that TERT expression was sig-nificantly associated with worse PFS even when controlling for other known predictors of clinical outcome including TPM, CDKN2A/B loss, 1p/22q status and WHO grade (HR 1.85 [95% CI 1.33-2.57], p=0.00024). CON¬CLUSION: TERT expression is a novel independent biomarker of outcome for meningiomas identifiable in up to one-third of cases that may be utilized to reclassify tumors to a higher WHO grade. | eng |
| dc.identifier.doi | 10.1093/neuonc/noaf201.0201 | |
| dc.identifier.eissn | 1523-5866 | |
| dc.identifier.issn | 1522-8517 | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/27984 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Oxford University Press (OUP) | |
| dc.relation.ispartof | Neuro-Oncology | |
| dc.rights.uri | N/A | |
| dc.title | Tert expression in meningiomas predicts progression-free survival independent of tert promoter mutation | eng |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | Supplement_5 | |
| oaire.citation.title | Neuro-Oncology | |
| oaire.citation.volume | 27 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |
| person.familyName | Castelo-Branco | |
| person.givenName | Pedro | |
| person.identifier.ciencia-id | E015-7F8F-5CA1 | |
| person.identifier.orcid | 0000-0002-3453-3978 | |
| relation.isAuthorOfPublication | bb25b5ad-1769-42be-a7d3-8fe76215aa23 | |
| relation.isAuthorOfPublication.latestForDiscovery | bb25b5ad-1769-42be-a7d3-8fe76215aa23 |